Literatur
Bauer M, Whybrow PC, Angst J et al; World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43
Damm J, Eser D, Schule C et al (2009) Wirksamkeit antidepressiver Therapieverfahren auf depressive Kernsymptome. Nervenarzt 80:515–520
DeRubeis RJ, Fournier JC, Fawcett J (2010) Depression severity and effect of antidepressant medications – author reply. JAMA 303:1599
Elkin I (2010) Depression severity and effect of antidepressant medications. JAMA 303:1596–1597
Finkelstein MM (2010) Depression severity and effect of antidepressant medications. JAMA 303:1596–1597
Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455
Montgomery SA, Möller HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111–118
Sartorius N, Baghai TC, Baldwin DS et al (2007) Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 10 (Suppl 1):S1–S207
Interessenkonflikt
T.C. Baghai war als Referent für die Firmen Astra-Zeneca, Essex, Glaxo-Smith-Kline, Servier und Wyeth tätig.
H.J. Möller war als Referent oder Berater für die folgenden Firmen tätig: AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Schering-Plough, Schwabe, Sepracor, Servier und Wyeth.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baghai, T., Möller, H. & Nitschmann, S. Effektivität der antidepressiven Therapie bei Patienten mit mäßig ausgeprägter depressiver Symptomatik. Internist 51, 1456–1458 (2010). https://doi.org/10.1007/s00108-010-2747-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-010-2747-6